David Geer

Dr. David Geer has worked over 15 years in the biopharmaceutical industry in the areas of process development and commercialization of live virus vaccines, biological and small molecule drug products. David started his professional career at Merck and Co., Inc with the responsibility for technical support and project leadership during late stage product development.

Over the years, he has contributed to many novel therapies serving global unmet medical needs such as GARDASIL®, the first vaccine for cervical cancer and KEYTRUDA®, the first FDA-approved anti PD1 immunotherapy medicine for melanoma and lung cancer. In 2017, David joined Shire / Takeda where he was Director of External Technical Operations supporting manufacturing of commercial products, process optimizations and troubleshooting quality deviations. Recently, David joined Lyndra Therapeutics as Head of Manufacturing Science and Technology and his team is focusing on development of an exciting oral dosage form technology for ultra-long controlled drug delivery of small molecules. David currently resides in Perkasie, PA.

David's PhD Advisor was Professor Stelios Andreadis